

## **Lupin's US Subsidiary Enters Into Collaboration to Promote Atopiclair™ Nonsteroidal Cream to Pediatricians in the U.S.**

<b>BSE : 500257</b>	<b>NSE: LUPIN</b>	<b>REUTERS: LUPN.BO</b>	<b>BLOOMBERG: LPC IN</b>
---------------------	-------------------	-------------------------	--------------------------

**Mumbai, 3 March 2006:** Lupin Pharmaceuticals, Inc. (LPI), a wholly-owned subsidiary of Lupin Ltd., has announced that it has entered into an agreement with Chester Valley Pharmaceuticals in the United States to promote Atopiclair™ Nonsteroidal Cream to pediatricians. Atopiclair™ Nonsteroidal Cream is the first prescription medical device authorized by the US FDA to relieve symptoms of atopic dermatitis and allergic contact dermatitis.

Under the terms of the agreement, LPI's pediatric sales force will promote Atopiclair™ Nonsteroidal Cream to pediatric prescribers. LPI has created a dedicated national pediatric sales force to promote its third generation cephalosporin, Suprax®. Chester Valley Pharmaceuticals will continue to promote Atopiclair™ Nonsteroidal Cream to dermatologists and other prescribers.

Announcing the agreement, LPI President Vinita Gupta said: "We are pleased to enter into this relationship with Chester Valley Pharmaceuticals. We believe that LPI's pediatric sales force will expand the usage of this new product for atopic dermatitis and allergic contact dermatitis among pediatricians."

Bob Moccia, President and CEO of Chester Valley Pharmaceuticals said: "This new relationship with Lupin will permit Chester Valley Pharmaceuticals to focus its recently expanded sales force on the promotion of Atopiclair™ Nonsteroidal Cream and Benziq™ Gels and Wash to dermatologists."

### **About Lupin**

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state of the art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

During the first 9 months of the current financial year, the Company's Revenues and PAT were Rs.12267 million and Rs.1325 million respectively.

### **About Chester Valley Pharmaceuticals**

Based in Malvern, Pennsylvania, Chester Valley Pharmaceuticals is a specialty dermatology company focused on acquiring, in-licensing and developing branded prescription products for sale in the United States. For more information, go to [www.chestervalleypharma.com](http://www.chestervalleypharma.com).

### **For further information contact:**

Raju Kane

The Source

Tel. +91 22 27564822, 27566683

Telefax : +91 22 27576555

Mobile : +91 98200 45656

E-mail: [rajukane@sourcepr.com](mailto:rajukane@sourcepr.com)